GT Biopharma Inc. (GTBP) Financial Statements (2024 and earlier)

Company Profile

Business Address 8000 MARINA BLVD
BRISBANE, CA 94005
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:14,00016,50832,0005,2972860
Cash and cash equivalents1,0795,6729,2185,2972860
Short-term investments12,89310,83623,011   
Other undisclosed cash, cash equivalents, and short-term investments28 (229)   
Prepaid expense   19036424630
Other undisclosed current assets5654(21)   
Total current assets:14,05616,56232,1695,66127490
Noncurrent Assets
Operating lease, right-of-use asset53165   
Property, plant and equipment      35
Intangible assets, net (including goodwill), including:      25,262
Other undisclosed intangible assets, net (including goodwill)      25,262
Deposits noncurrent assets  9  1212
Other undisclosed noncurrent assets     110 
Total noncurrent assets:53174  12225,309
TOTAL ASSETS:14,10916,73632,1695,66139625,399
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,5234,80910,0908,3776,3483,217
Interest and dividends payable 4,8382,029 
Accounts payable4,3283,1408,1892,2431,9401,762
Accrued liabilities1,1951,6691,9011,2962,3791,455
Debt   3126,30313,20710,673
Deferred rent credit      8
Derivative instruments and hedges, liabilities 19138383  
Due to related parties    100
Other undisclosed current liabilities1,110110 3115131
Total current liabilities:6,6334,93810,25935,09419,70614,029
Noncurrent Liabilities
Liabilities, other than long-term debt  64    
Operating lease, liability  64   
Total noncurrent liabilities:  64    
Total liabilities:6,6335,00210,25935,09419,70614,029
Equity
Equity, attributable to parent, including:7,47611,73421,910(29,433)(19,310)11,370
Preferred stock11 3  
Common stock13332527051
Additional paid in capital689,539686,168674,348566,309548,118540,171
Accumulated deficit(682,065)(674,468)(653,584)(595,628)(567,332)(528,685)
Other undisclosed equity, attributable to parent   1,114(169)(166)(167)
Total equity:7,47611,73421,910(29,433)(19,310)11,370
TOTAL LIABILITIES AND EQUITY:14,10916,73632,1695,66139625,399

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues
(gain on Disposition of Assets for Financial Service Operations)
   31,979   
Gross profit:   31,979   
Operating expenses(13,576)(21,257)(57,515)(6,764)(16,056)(250,069)
Other undisclosed operating income (loss)   (31,979)13,528  
Operating income (loss):(13,576)(21,257)(57,515)6,764(16,056)(250,069)
Nonoperating income (expense)5,979373(498)21,532(22,591)(9,117)
Investment income, nonoperating    12,598(4,599)(228,515)
Interest and debt expense(213)31 3,003(2,128)(9,117)
Income (loss) from continuing operations before equity method investments, income taxes:(7,810)(20,853)(58,013)31,299(40,775)(268,303)
Other undisclosed income from continuing operations before income taxes     2,1289,117
Income (loss) from continuing operations:(7,810)(20,853)(58,013)31,299(38,647)(259,186)
Income (loss) before gain (loss) on sale of properties:(58,013)31,299(38,647)(259,186)
Net income (loss):(7,810)(20,853)(58,013)31,299(38,647)(259,186)
Other undisclosed net income (loss) attributable to parent213(31) (59,595)  
Net loss available to common stockholders, diluted:(7,597)(20,884)(58,013)(28,296)(38,647)(259,186)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net income (loss):(7,810)(20,853)(58,013)31,299(38,647)(259,186)
Comprehensive income (loss), net of tax, attributable to parent:(7,810)(20,853)(58,013)31,299(38,647)(259,186)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: